BioSpace News Archive

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) announced today that the U.S. Food and Drug Administration (“FDA”), after reviewing safety data on the program, has removed the partial clinical hold on patient enrollment for its MT-0169 trial.

Elevar Therapeutics, Inc. announced its participation plans for the 2023 American Society of Clinical Oncology Annual Meeting in Chicago and the 2023 BIO International Convention in Boston.

NurExone Biologic Inc., a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce a pioneering collaboration with the German company, Particle Metrix, a leading provider of particle analysis devices.

Ocean Biomedical, Inc. announced that an equity analyst coverage report has been issued by Taglich Brothers with a price target of $20 per share.

Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced that members of its management team will participate in the following upcoming investor conferences.

Exact Sciences Corp. announced that the company has been certified as a 2023 Great Place To Work® for the fifth consecutive year.

NeuroTrauma Sciences, LLC (NTS), a private biopharmaceutical company developing neuroprotective therapeutics for treating patients with stroke and other CNS injuries, today announced that it has commenced dosing in a Phase 1 study of its investigational drug NTS-104, in healthy volunteers.

The first patient has been dosed in a Phase 2 study (AVX-201) being run by biotechnology company Aravax, which is developing the novel therapy PVX108 for the safe and convenient treatment of peanut allergy.

BIORCHESTRA today announced that Dr. Branden Ryu, Founder, Chairman, and Chief Executive Officer, has accepted an invitation to present the company’s discovery program, brain-specific gene targeted siRNA-BTRiN and non human primate (NHP) study outcomes from its lead program – BMD-001 – at the 2023 Biotechnology Innovation Organization International Convention.

The Max Foundation announced the launch of its Max Access Solutions program to deliver access to treatment for HR+/HER2- advanced breast cancer patients in collaboration with leading oncologists in low and middle-income countries.